Lahooti and colleagues used a class 2 antagonist with D-Phe12 substitution to successfully target their ultrasmall paramagnetic iron oxide nanoparticles (USPION) to GRPR-positive breast cancer xenograft in vivo [36]. Here, GRPR is linked to breast carcinoma.